Holen Sie sich die Stockscreener-App
114.60
2.84%
3.16
Handel nachbörslich:
114.57
-0.03
-0.03%
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
BioNTech’s New Study on PDAC Treatment: Key Insights for Investors - TipRanks
BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN
Pfizer and BioNTech’s New Shingles Vaccine Study: What Investors Need to Know - TipRanks
BioNTech’s BNT327 Trial: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks
BioNTech’s Promising Lung Cancer Trial: A Potential Game-Changer for NSCLC Treatment - TipRanks
BioNTech Announces Ryan Richardson to Step Down from the Management Board17.07.25News - Ariva
BioNTech’s DYNASTY-Breast02 Study: A New Hope for Metastatic Breast Cancer? - TipRanks
OneDigital Investment Advisors LLC Makes New Investment in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks
BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment? - TipRanks
BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks
Regeneron and BioNTech’s Promising Lung Cancer Trial: What Investors Need to Know - TipRanks
BioNTech SE Receives Buy Rating from BMO Capital with $143 Price Target - AInvest
Genmab and BioNTech’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
GAMMA Investing LLC Sells 334 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks
Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope in Cancer Treatment - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech’s BNT151 Study Update: Early Termination and Market Implications - TipRanks
BioNTech ADR Earns Relative Strength Rating Upgrade - MSN
Biontech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
What is HC Wainwright’s Forecast for BioNTech Q3 Earnings? - Defense World
BioNTech ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily
BioNTech’s Promising Phase II Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech SE’s Promising Study on Pancreatic Cancer Treatment: What Investors Need to Know - TipRanks
BioNTech’s BNT327: A Promising Phase II Trial for Small-Cell Lung Cancer - TipRanks
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Zacks Investment Research
Equities Analysts Issue Forecasts for BioNTech Q4 Earnings - Defense World
BioNTech (BNTX) – Analysts’ Recent Ratings Changes - Defense World
Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com
HC Wainwright Estimates BioNTech’s Q4 Earnings (NASDAQ:BNTX) - Defense World
Market Update: Abercrombie & Fitch Co (ANF) Sees Positive Movement, Closing at 75.00 - DWinneX
Gaining Ground: fuboTV Inc (FUBO) Closes Higher at 3.26, Up 2.84 - DWinneX
Market Resilience: Nerdy Inc (NRDY) Finishes Strong at 1.63, Up 2.52 - DWinneX
5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga
Riding the Waves: A Guide to Investing in ARBE Stock - investchronicle.com
BMY Reports Positive Data On Sotyktu From Arthritis Study - Barchart.com
Erasca Inc (ERAS) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
CureVac stock soars about 30% after BioNTech agrees to acquire co By Investing.com - Investing.com South Africa
Vaccine stocks muted as investors assess Kennedy’s overhaul of key panel - The Globe and Mail
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading - Benzinga
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio? - The Globe and Mail
Is BioNTech Stock A Buy On Major $11 Billion Cancer-Drug Deal? - Barchart.com
Bristol Myers Collaborates With BNTX for Oncology Candidate - sharewise
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results - Yahoo Finance
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
Bristol-Myers and BioNTech: Oncology Collaboration Further Solidifies BNT327's Potential - Morningstar
Bristol Myers Collaborates With BNTX For Oncology Candidate - Barchart.com
MRNA Seeks FDA Nod for Updated COVID-19 Vaccine - Yahoo Finance
0.26%
5.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):